NSC745885|cas:4219-52-7|西域试剂

NSC745885,98.0%

产品编号：Bellancom-119198| CAS NO：4219-52-7| 分子式：C₁₄H₆N₂O₂S| 分子量：266.27

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-119198	￥2500.00	杭州北京（现货）
Bellancom-119198	￥4500.00	杭州北京（现货）
Bellancom-119198	￥13000.00	杭州北京（现货）
Bellancom-119198	￥18000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

NSC745885

产品介绍

NSC745885 是一种有效的抗肿瘤 (anti-tumor) 试剂，对多种癌细胞株有选择性毒性，但对正常细胞没有毒性。NSC745885 是一种有效的 EZH2 的下调因子通过蛋白酶体降解途径。NSC745885 为晚期膀胱癌和口腔鳞癌的研究提供了可能性。

生物活性

NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers.

体外研究

NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC₅₀ of NSC745885 is 0.85 μM after 72 hours’ treatment.
NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner.
NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	SAS cells is obtained from a poorly differentiated human squamous cell carcinoma
Concentration:	0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM
Incubation Time:	24, 48, or 72 hours
Result:	Decreases SAS cells growth as a time and dose-dependent manner.

Apoptosis Analysis

Cell Line:	SAS cells is obtained from a poorly differentiated human squamous cell carcinoma
Concentration:	0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM
Incubation Time:	24 hours
Result:	Decreases SAS cells growth as a time and dose-dependent manner.

Western Blot Analysis

Cell Line:	SAS cells is obtained from a poorly differentiated human squamous cell carcinoma
Concentration:	0.5 μM, 1 μM, 1.5 μM, 2 μM
Incubation Time:	24 or 48 hours
Result:	Increased cleaved caspase-3 expression and decreased XIAP expression.

体内研究
(In Vivo)

NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old NOD/SCID (NOD.CB17 Prkdc^scid/J) mice
Dosage:	2 mg/kg
Administration:	Intraperitoneal injection; 2 mg/kg; once daily; 10 days
Result:	Inhibited engrafted tumors growth in vivo.

体内研究

NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old NOD/SCID (NOD.CB17 Prkdc^scid/J) mice
Dosage:	2 mg/kg
Administration:	Intraperitoneal injection; 2 mg/kg; once daily; 10 days
Result:	Inhibited engrafted tumors growth in vivo.

体内研究

NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old NOD/SCID (NOD.CB17 Prkdc^scid/J) mice
Dosage:	2 mg/kg
Administration:	Intraperitoneal injection; 2 mg/kg; once daily; 10 days
Result:	Inhibited engrafted tumors growth in vivo.